Edgewise Sells Sevasemten for Up to $2.65 Billion & Goes All-In on Heart Drugs
Edgewise sells Sevasemten to Servier for up to $2.65B and shifts focus to heart drugs for cardiomyopathy and heart failure.
/ 1653 items
#XY↓
Immuneering’s Pancreatic Cancer Drug Doubles Survival to 17.3 Months — Stock Falls Anyway
Immuneering's drug combo doubled pancreatic cancer survival (17.3 vs 8.5 months) and looked safe, but shares dropped.
Bernstein Says Sell SMMT: Why Summit Therapeutics Stock Could Drop More
Bernstein remains bearish on Summit, citing doubts about trial success and expecting weak results ahead.
Avenzo Goes Public: $215 Million Merger with Rallybio to Fight Cancer
Rallybio merges with Avenzo to boost cancer drug development; new AVZO company gets $215M funding and Nasdaq listing.
Cardiff Oncology Downgraded by Two Analysts After Nerviano Terminates Onvansertib License
Cardiff was downgraded by TD Cowen and H.C. Wainwright after Nerviano Medical Sciences terminated the onvansertib license agreement. Company calls termination invalid and is fighting in court.
Waldencast Sells Obagi Medical – Now All-In on Milk Makeup Growth
Waldencast sells Obagi Medical to Bridgepoint for up to $460M, pays debt, and focuses fully on Milk Makeup growth.